VivoSeq
Other

Poisoning

20

Pipeline Programs

1

Active Trials

10

Companies Involved

Poisoning is an emerging landscape with 20 programs across 10 companies. The most active players are Iperboreal Pharma Srl, Boehringer Ingelheim, Azurity Pharmaceuticals. 5 therapies are approved with 6 more in late-stage development.

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

89/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

96%

Small molecule

23 of 24 classified programs — the dominant modality here.

4%ALL OTHERSCell therapy14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Trial Status

25

clinical trials

Completed16 · 64%
Unknown status6 · 24%
Withdrawn2 · 8%
Recruiting1 · 4%

Trial Activity

25 trials

Supportive Measures in Treatment of Aluminum Phosphide Poisoning
Completed··Phase 4·NCT03879356·44 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)